---
title: The TAME study and its objectives
videoId: sFbghkE0WYo
---

From: [[⁨cleoabram⁩]] <br/> 

Metformin, a medication widely used for decades by individuals with diabetes to manage blood sugar, has recently garnered significant attention for a different potential application: anti-aging <a class="yt-timestamp" data-t="00:00:20">[00:00:20]</a>. This affordable drug, costing pennies per pill, is now being explored by researchers and some wealthy individuals for its potential to extend lifespan <a class="yt-timestamp" data-t="00:00:30">[00:00:30]</a>.

## Separating Science from "Snake Oil"

The field of anti-aging often faces skepticism due to the prevalence of "charlatans" selling unproven remedies <a class="yt-timestamp" data-t="00:00:52">[00:00:52]</a>. However, legitimate scientific inquiry into aging, led by experts like Dr. Nir Barzilai, aims to understand how to delay the effects of aging, rather than promising a "fountain of youth" that makes old people young again <a class="yt-timestamp" data-t="00:01:15">[00:01:15]</a>.

The core idea is that aging is a biological process where bodies accumulate damage over time <a class="yt-timestamp" data-t="00:02:02">[00:02:02]</a>. This accumulation of damage drives the onset of common diseases like cancer, heart disease, and Alzheimer's, which are primary causes of death <a class="yt-timestamp" data-t="00:01:41">[00:01:41]</a>. If this "biology of aging" can be delayed, it could push back the incidence of these diseases and prolong healthy life <a class="yt-timestamp" data-t="00:01:55">[00:01:55]</a>.

## The UK Study and Metformin's Potential

In 2014, a compelling retrospective study from the UK involving approximately 180,000 people brought Metformin into the anti-aging discussion <a class="yt-timestamp" data-t="00:02:23">[00:02:23]</a>. The study compared mortality rates across three groups:
*   Diabetics taking metformin <a class="yt-timestamp" data-t="00:02:36">[00:02:36]</a>.
*   Diabetics taking other non-metformin drugs <a class="yt-timestamp" data-t="00:02:40">[00:02:40]</a>.
*   Non-diabetics not taking diabetes drugs <a class="yt-timestamp" data-t="00:02:43">[00:02:43]</a>.

The study revealed that diabetics not on metformin had double the mortality rate compared to non-diabetics <a class="yt-timestamp" data-t="00:02:47">[00:02:47]</a>. Strikingly, people with diabetes taking metformin, who were often more obese and sicker to begin with, exhibited *less* mortality than individuals *without* diabetes <a class="yt-timestamp" data-t="00:02:54">[00:02:54]</a>. This unexpected finding suggested a potential anti-aging effect of metformin beyond its diabetes management role <a class="yt-timestamp" data-t="00:03:08">[00:03:08]</a>.

### Caveats and the Need for Further Research

While intriguing, the UK study had limitations:
*   It was a retrospective correlation, meaning it looked back at existing data <a class="yt-timestamp" data-t="00:03:19">[00:03:19]</a>. It could not definitively prove that metformin *caused* the reduced mortality <a class="yt-timestamp" data-t="00:03:24">[00:03:24]</a>.
*   All participants taking metformin were diabetic <a class="yt-timestamp" data-t="00:03:27">[00:03:27]</a>. It was not clear if the "dying less" effect would apply to people without diabetes <a class="yt-timestamp" data-t="00:03:31">[00:03:31]</a>.

Though metformin's mechanism in diabetes (controlling blood sugar levels) is well understood <a class="yt-timestamp" data-t="00:03:40">[00:03:40]</a>, its potential anti-aging mechanism in non-diabetics is less clear <a class="yt-timestamp" data-t="00:03:56">[00:03:56]</a>. Existing studies show metformin having anti-aging effects in healthy mice and worms <a class="yt-timestamp" data-t="00:04:12">[00:04:12]</a>, but more comprehensive human trials are needed to confirm its efficacy in humans without diabetes <a class="yt-timestamp" data-t="00:04:17">[00:04:17]</a>.

## The TAME Study: A Landmark Initiative

To address these unknowns, Dr. Nir Barzilai is leading a groundbreaking nationwide study called TAME, which stands for **Targeting Aging with Metformin** <a class="yt-timestamp" data-t="00:04:36">[00:04:36]</a>.

### Objectives of the TAME Study
The TAME study is designed as a proper randomized controlled trial <a class="yt-timestamp" data-t="00:04:29">[00:04:29]</a>. Participants will be randomly assigned to receive either metformin or a placebo <a class="yt-timestamp" data-t="00:04:30">[00:04:30]</a>. Its primary objective is to gain FDA approval to repurpose metformin as a drug that explicitly targets aging <a class="yt-timestamp" data-t="00:04:48">[00:04:48]</a>.

If successful, the TAME study could revolutionize medicine by confirming that aging itself is a treatable condition <a class="yt-timestamp" data-t="00:05:06">[00:05:06]</a>. Proving that something can delay the accumulation of biological damage and push back the diseases that lead to mortality would be an immense medical breakthrough <a class="yt-timestamp" data-t="00:05:10">[00:05:10]</a>. The fact that this "something" might be a cheap, readily available drug like metformin makes the prospect even more impactful <a class="yt-timestamp" data-t="00:05:17">[00:05:17]</a>.

## Considerations for Individuals

While the TAME trial is underway, individuals considering taking metformin for anti-aging without diabetes must weigh several factors <a class="yt-timestamp" data-t="00:05:44">[00:05:44]</a>:

*   **Existing Studies**: One must assess the strength of current, mostly correlational, studies <a class="yt-timestamp" data-t="00:05:52">[00:05:52]</a>.
*   **Urgency of Aging**: The perceived urgency of delaying aging is a personal choice <a class="yt-timestamp" data-t="00:05:57">[00:05:57]</a>.
*   **Side Effects**: Metformin has common initial side effects, including early satiety, upset stomach, and diarrhea, typically in the first week of use <a class="yt-timestamp" data-t="00:06:07">[00:06:07]</a>. It also impacts how the body responds to exercise, leading to less muscle growth even with increased capacity <a class="yt-timestamp" data-t="00:06:20">[00:06:20]</a>.

The TAME study's results will provide crucial evidence to inform these individual calculations and potentially reshape our understanding of aging and disease prevention. The success of this [[research_on_metformins_effects_on_aging | research]] could significantly reduce the global burden of diseases like heart disease (18 million annual deaths), cancer (10 million annual deaths), and Alzheimer's (55 million affected) <a class="yt-timestamp" data-t="00:07:44">[00:07:44]</a>.